No Bubble Here: Profiting From Idiocy
Let’s face it: Health care spending isn't going anywhere. People are getting older. Older people get sick more often. They face life-threatening diseases more often. And they are desperate for cures. I understand why selling stocks in many sectors that will bear the impact from current threats might seem to be a good idea. But biotech? Nothing could be more stupid.
You Must Be A Subscriber To View This Content.
If you are already a subscriber, click the login button below to get access. Not yet a subscriber? Checkout our publication below and get access today!
Ray Blanco’s FDA Trader
Ray Blanco’s FDA Trader focuses on medical tech stocks with prices that move based on triggers generally unknown to the market. It is designed to alert you to breakout moves in the medical markets that could ultimately drive huge stock market gains. It’s the single best way to connect the dots that link today’s dynamic, innovative medical market.